Sandoz Champions Stability As It Returns To Growth In Q2
Investments In Biosimilars Will Spearhead Financial Goals
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
You may also be interested in...
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”